OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC)
CDK8 is a transcriptional cyclin-dependent kinase and considered as a potential target in colon cancer therapeutics. Here, a novel selective CDK8 inhibitor was identified against colon cancer in vivo.
This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the treatment, the invest
Interventions: Capecitabine plus bevacizumab therapy Capecitabine:2,000mg/m2 twice daily (orally, day1 after dinner:day8 after breakfast) Bevacizumab:7.5mg/kg day 1 The treatment is repeated every thr
